Fisher & Paykel Healthcare Corporation Limited logo

Fisher & Paykel Healthcare provides FY22 revenue guidance

Guidance22 March 2022FPHHealthcare

News Release
STOCK EXCHANGE LISTINGS: NEW ZEALAND (FPH), AUSTRALIA (FPH)


Fisher & Paykel Healthcare provides FY22 revenue guidance


Auckland, New Zealand, 23 March 2022 - Fisher & Paykel Healthcare Corporation Limited

today provided revenue guidance for the financial year ending 31 March 2022.


At current exchange rates, the company expects full year operating revenue for the 2022

financial year to be in the range of $1.675 billion to $1.70 billion.


Managing Director and Chief Executive Officer Lewis Gradon said, “Our second half hospital

consumables revenue is currently tracking to be similar to the hospital consumables revenue

that we reported in the first half of the 2022 financial year. This is consistent with reports of the

increasing prevalence of the Omicron variant over the last two months and its associated lower

respiratory intervention requirements, as well as a relatively mild flu season in the Northern

Hemisphere.

“In our Homecare product group, growth in sales of our OSA masks is currently tracking above

our first half growth rate despite supply constraints of treatment hardware in the market.

“Freight rates remain elevated and for the 2022 financial year are expected to impact our long-

term gross margin target of 65% by approximately 250 basis points.

“Regardless of how COVID-19 effects unfold over the short term, we are confident our business

is well-placed to contribute to a positive change in clinical practice and improving outcomes for

respiratory patients in general over the long term”, concluded Mr Gradon.

The company intends to release on Wednesday, 25 May 2022 its financial results for the year

ending 31 March 2022.


About Fisher & Paykel Healthcare

Fisher & Paykel Healthcare is a leading designer, manufacturer and marketer of products and

systems for use in acute and chronic respiratory care, surgery and the treatment of obstructive

sleep apnea. The company’s products are sold in over 120 countries worldwide. For more

information about the company, visit our website www.fphcare.com

.


Media & Investor Contacts:

Karen Knott

GM Corporate Communications

karen.knott@fphcare.co.nz

+64 21 713 911

Hayden Brown

Investor Relations Manager

hayden.brown@fphcare.co.nz

+64 27 807 8073




Authorised by Fisher & Paykel Healthcare Corporation Limited’s Board of Directors.

Data sourced from publicly available filings. Our datasets may not be complete. Automated analysis can produce errors. If you believe any data on this page is incorrect, please contact us at hello@nzxplorer.co.nz. For informational purposes only. Not investment advice.

Other issuers discussed similar conditions around this time

Matched by meaning across NZX announcement text, not keywords — based on our semantic index of announcement bodies.